AstraZeneca Results Presentation Deck

Financial priorities FY 2020 results underpinned the strategic journey Deleveraging/dividend growth As cash flow improves, deleveraging and progressive dividend policy • Unchanged priorities for capital allocation 23 Cash-flow growth 2020: continued improvement in cash-flow metrics; dividend cover • 2021: anticipate further improvement in cash flow Changes at CER. Revenue growth +10% growth in total revenue in 2020 Operating leverage • 59% ratio of core operating expenses to total revenue (vs. 60% in 2019) • 17% growth in core operating profit 28% core operating profit margin. despite 2% lower core 001 B

View entire presentation